protein

Recombinant Human PDGFRa / CD140a Protein (His tag)

MBS2546183

0.05 mg

405 USD

Recombinant Protein

Recombinant Human PDGFRa / CD140a Protein (His tag)

[PDGFRa / CD140a]

[PDGFRA, CD140a, MGC74795, PDGFR2, Rhe-PDGFRA]

[platelet-derived growth factor receptor alpha isoform 1; Platelet-derived growth factor receptor alpha; platelet-derived growth factor receptor alpha; platelet derived growth factor receptor alpha; Alpha platelet-derived growth factor receptor; Alpha-type platelet-derived growth factor receptor; CD140 antigen-like family member A; CD140a antigen; Platelet-derived growth factor alpha receptor; Platelet-derived growth factor receptor 2; PDGFR-2; CD_antigen: CD140a]

[PDGFRa / CD140a]

[PDGFRA; PDGFRA; CD140A; PDGFR2; PDGFR-2; PDGFR2; RHEPDGFRA; PDGF-R-alpha; PDGFR-alpha; PDGFR-2]

Human Cells

1089

> 97 % as determined by SDS-PAGE

Lyophilized from sterile PBS,pH 7.4, 5% Trehalose, 5% mannitol, 0.01 Tween-80

Store it under sterile conditions at -20°C to -80°C upon receiving. Recommend to aliquot the protein into smaller quantities for optimal storage.

The recombinant human PDGFRalpha consists of 512 amino acids and predicts a molecular mass of 57.7 kDa. By SDS-PAGE under reducing conditions, the apparent molecular mass of rhPDGFRalpha is approximately 90-100 kDa due to the glycosylation.

Testing Data (TD)

Source: Human. Predicted N Terminal: Gln 24. Bio-Activity: Measured by its ability to bind human PDGFC-Fc in functional ELISA.

Endotoxin: < 1.0 EU per ug of the protein as determined by the LAL method. Reconstitution: It is recommended that sterile water (200uL) be added to the vial to prepare a stock solution of 0.25 mg/mL. Concentration is measured by UV-Vis.

Background: PDGFRA, also known as CD140a, together with the structurally homolog protein PDGFRB (CD140b), are cell surface receptors for members of the platelet-derived growth factor family. They are members of the class III subfamily of receptor tyrosine kinase (RTKs) with the similar structure characteristics of five immunoglobulin-like domains in their extracellular region and a split kinase domain in their intracellular region. PDGFRA is expressed in oligodendrocyte progenitor cells and mesothelial cell, and binds all three ligand isoforms PDGF-AA, PDGF-BB and PDGF-AB with high affinity, whereas PDGFRB dose not bind PDGF-AA. PDGFRA plays an essential role in regulating proliferation, chemotaxis and migration of mesangial cells. Recent studies have indicated that PDGFRA acts as a critical mediator of signaling in testis organogenesis and Leydig cell differentiation, and in addition, particularly important for kidney development. Additionally, PDGFRA is involved in tumor angiogenesis and maintenance of the tumor microenvironment and has been implicated in development and metastasis of Hepatocellular carcinoma (HCC). PDGFRA may represent a potential therapeutic target in thymic tumours. PDGFRA gene amplification rather than gene mutation may be the underlying genetic mechanism driving PDGFRA overexpression in a portion of gliomas. Description: A DNA sequence encoding the extracellular domain (Met 1-Glu 524) of human PDGFRalpha (NP_006197.1) was fused with a polyhistidine tag at the C-terminus.

5453870

NP_006197.1

NM_006206.5

P16234

ATF-2 Transcription Factor Network Pathway (138006); Adaptive Immune System Pathway (366160); Angiogenesis Pathway (198772); Calcium Signaling Pathway (83050); Calcium Signaling Pathway (459); Cardiac Progenitor Differentiation Pathway (712094); Constitutive PI3K/AKT Signaling In Cancer Pathway (685535); Cytokine-cytokine Receptor Interaction Pathway (83051); Cytokine-cytokine Receptor Interaction Pathway (460); DAP12 Interactions Pathway (685549)

This gene encodes a cell surface tyrosine kinase receptor for members of the platelet-derived growth factor family. These growth factors are mitogens for cells of mesenchymal origin. The identity of the growth factor bound to a receptor monomer determines whether the functional receptor is a homodimer or a heterodimer, composed of both platelet-derived growth factor receptor alpha and beta polypeptides. Studies suggest that this gene plays a role in organ development, wound healing, and tumor progression. Mutations in this gene have been associated with idiopathic hypereosinophilic syndrome, somatic and familial gastrointestinal stromal tumors, and a variety of other cancers. [provided by RefSeq, Mar 2012]

PDGFRA: a receptor tyrosine kinase of the PDGFR family that binds members of the platelet-derived growth factor family. The identity of the growth factor bound determines whether the functional receptor is a homodimer or a heterodimer, composed of both PDGFR-alpha and -beta. Ligand binding induces receptor dimerization and autophosphorylation. Particularly important for kidney development since mice heterozygous for the receptor exhibit defective kidney phenotypes. Chromosomal rearrangments activate PDGFRalpha by fusion to BCR, causing atypical chronic myelogenous leukemia (CML), and to FIP1L1, causing idiopathic hypereosinophilic syndrome. Activating point mutations cause a minority of gastrointestinal stromal tumors (GIST). Promoter polymorphisms linked to neural tube defects including spina bifida, verified by mouse mutant model. Inhibitors: Gleevec, Sutent. OMIM: Two alternatively-spliced isoforms have been described. Protein type: EC 2.7.10.1; Kinase, protein; Membrane protein, integral; Oncoprotein; PDGFR family; Protein kinase, TK; Protein kinase, tyrosine (receptor); TK group. Chromosomal Location of Human Ortholog: 4q12. Cellular Component: cytoplasm; integral to plasma membrane; intrinsic to plasma membrane; membrane; nucleus; plasma membrane; protein complex. Molecular Function: phosphatidylinositol-4,5-bisphosphate 3-kinase activity; platelet-derived growth factor alpha-receptor activity; platelet-derived growth factor binding; platelet-derived growth factor receptor binding; protein binding; protein homodimerization activity; protein kinase activity; Ras guanyl-nucleotide exchange factor activity; transmembrane receptor protein tyrosine kinase activity; vascular endothelial growth factor receptor activity. Biological Process: cardiac myofibril assembly; cell activation; elevation of cytosolic calcium ion concentration; embryonic cranial skeleton morphogenesis; embryonic digestive tract morphogenesis; embryonic skeletal morphogenesis; luteinization; MAPKKK cascade; peptidyl-tyrosine phosphorylation; phosphoinositide-mediated signaling; platelet-derived growth factor receptor signaling pathway; positive regulation of cell migration; positive regulation of cell proliferation; positive regulation of DNA replication; positive regulation of fibroblast proliferation; positive regulation of phosphoinositide 3-kinase activity; positive regulation of phosphoinositide 3-kinase cascade; protein amino acid autophosphorylation; regulation of chemotaxis; regulation of phosphoinositide 3-kinase cascade; wound healing. Disease: Gastrointestinal Stromal Tumor; Hypereosinophilic Syndrome, Idiopathic

0.05 mg

405 USD

0.1 mg

635